Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis

Abstract

Although the regular consumption of resveratrol has been known to improve glucose homeostasis and reverse insulin resistance in type 2 diabetes mellitus (T2DM), the reported results are inconsistent. Thus, we aimed to assess the effects of resveratrol on glycemic control and insulin sensitivity among patients with T2DM. We searched for relevant articles published until June 2017 on PubMed-Medline, Embase, Cochrane Library, and Web of Science. Randomized controlled trials in T2DM patients administered with resveratrol as intervention were included. After study selection, quality assessment and data extraction were performed independently by two authors, and STATA and RevMan software were used for statistical analysis. Nine randomized controlled trials involving 283 participants were included. Meta-analysis showed that resveratrol significantly improved the fasting plasma glucose ( −0.29 mmol/l, 95% CI: −0.51, −0.06, p < 0.01) and insulin levels (−0.64 U/mL, 95% CI: −0.95, −0.32, p < 0.0001). The drug also reduced homeostasis model assessment of insulin resistance (HOMA-IR) index, systolic blood pressure, and diastolic blood pressure among participants with T2DM. The changes in hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were negligible. Subgroup analysis comparing the resveratrol supplementation doses of < 100 mg/d versus ≥ 100 mg/d revealed a significant difference in fasting plasma glucose. In particular, the latter dose presented more favorable results. This meta-analysis provides evidence that supplementation of resveratrol may benefit management of T2DM.Electronic supplementary materialThe online version of this article (10.1186/s12986-017-0217-z) contains supplementary material, which is available to authorized users.

Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women

“…This is consistent with our previously published hypothesis that resveratrol might improve glucose uptake and/or reduce insulin demand by enhancing vasodilator function in skeletal muscle [39]. A recent meta-analysis has also shown that resveratrol can improve insulin sensitivity and insulin secretion in pancreatic β-cells and increase glucose uptake via Sirtuin-1 or adenosine monophosphate protein kinase mediated pathways [40]. Resveratrol could also facilitate expression of glucose transporter type-4 by acting on estrogen receptors on the endothelium and stimulate skeletal muscle glucose uptake [41], which could be an added metabolic benefit for postmenopausal women.…”

Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases

“…Disregarding this special effect, the insulin-sensitizing actions of resveratrol are complex and not completely elucidated. Part of the pharmacodynamic effects of this stilbene compound could derive from its capacity to modulate different pathways and molecular targets, including those downstream of the insulin receptor and mediated by AMP-activated protein kinase (AMPK) and sirtuin 1, as reported in clinical studies on diabetic patients and rodent models of IR, as well as in vitro experimental settings [147][148][149][150][151]. In these studies, treatment with resveratrol has proved to activate both fuel-sensors AMPK and sirtuin 1 in insulin-sensitive peripheral tissues, especially skeletal muscles.…”

The Effect of Resveratrol Supplementation on Cardio‐Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double‐Blind Controlled Trial

“…Antidiabetic effects of resveratrol have been investigated in recent years. A recent meta-analysis including nine trials has shown a significant reduction in serum levels of fasting glucose, insulin, and insulin resistance following resveratrol supplementation in diabetic patients (Zhu, Wu, Qiu, Yuan, & Li, 2017). Although, some studies reached nonsignificant results (Bashmakov et al, 2014;Goh et al, 2014;Timmers et al, 2016).…”